Benjamin S Teeter1, Kimberly B Garza2, T Lynn Stevenson3, Margaret A Williamson4, Megan L Zeek5, Salisa C Westrick6. 1. Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, 020 James E. Foy Hall, Auburn, AL 36849, United States. Electronic address: teetebs@auburn.edu. 2. Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, 020 James E. Foy Hall, Auburn, AL 36849, United States. Electronic address: kbl0005@auburn.edu. 3. Pharmacy Practice, Harrison School of Pharmacy, Auburn University, 1202 Walker Building, Auburn, AL 36849, United States. Electronic address: tls0002@auburn.edu. 4. Pharmacy Practice, Harrison School of Pharmacy, Auburn University, 1202 Walker Building, Auburn, AL 36849, United States. Electronic address: atkinmm@auburn.edu. 5. Harrison School of Pharmacy, Auburn University, 2316 Walker Building, Auburn, AL 36849, United States. Electronic address: mlz0001@auburn.edu. 6. Health Outcomes Research and Policy, Harrison School of Pharmacy, Auburn University, 020 James E. Foy Hall, Auburn, AL 36849, United States. Electronic address: westrsc@auburn.edu.
Abstract
OBJECTIVES: 1. Identify patient characteristics, awareness and knowledge associated with herpes zoster (HZ) vaccination status. 2. Identify self-reported reasons for not receiving Zostavax(®). 3. Assess the impact of a patient education program by measuring post-intervention interest in obtaining the Zostavax(®) vaccine across reasons for being unvaccinated. METHODS: A cross-sectional design with patients aged 60 years or older in 51 community pharmacies in Alabama and Florida was utilized. During the Introductory Pharmacy Practice Experience in summer 2013, 137 immunization-certified student pharmacists provided patient education on HZ and Zostavax(®) to unvaccinated patients using the Shingles Vaccine Information Statement. An interviewer-administered questionnaire assessed patient awareness of HZ, receipt of recommendations to receive Zostavax(®), and patient characteristics as well as vaccination status, reasons for being unvaccinated and interest in obtaining Zostavax(®) after the educational session. RESULTS: A total of 681 patients participated in a conversation with a student pharmacist regarding their HZ vaccination status. The majority were female (57.6%), white (84.6%), and unvaccinated (73.6%). Results from logistic regression suggest that participants were more likely to be vaccinated if they received a recommendation from a healthcare provider (OR=5.15), received the influenza vaccine during the previous year (OR=3.56), or knew that Zostavax(®) was recommended for individuals over 60 years of age (OR=3.55). The most frequently provided reasons for being unvaccinated were "haven't gotten around to it/forgot" (27.2%) and "didn't know it was needed" (27.1%). After the educational session, the majority (72.5%) of unvaccinated patients were interested in speaking with their pharmacist or physician about receiving Zostavax(®). Analysis suggests that interest differed across initial reason for being unvaccinated (χ(2)=64.44; p<0.01). IMPLICATIONS/ CONCLUSIONS: Recommendations from healthcare providers are valued by patients and can improve vaccination rates. The patient education program increased interest in receiving Zostavax(®) and this interest differed depending on the reason provided for being unvaccinated.
OBJECTIVES: 1. Identify patient characteristics, awareness and knowledge associated with herpes zoster (HZ) vaccination status. 2. Identify self-reported reasons for not receiving Zostavax(®). 3. Assess the impact of a patient education program by measuring post-intervention interest in obtaining the Zostavax(®) vaccine across reasons for being unvaccinated. METHODS: A cross-sectional design with patients aged 60 years or older in 51 community pharmacies in Alabama and Florida was utilized. During the Introductory Pharmacy Practice Experience in summer 2013, 137 immunization-certified student pharmacists provided patient education on HZ and Zostavax(®) to unvaccinated patients using the Shingles Vaccine Information Statement. An interviewer-administered questionnaire assessed patient awareness of HZ, receipt of recommendations to receive Zostavax(®), and patient characteristics as well as vaccination status, reasons for being unvaccinated and interest in obtaining Zostavax(®) after the educational session. RESULTS: A total of 681 patients participated in a conversation with a student pharmacist regarding their HZ vaccination status. The majority were female (57.6%), white (84.6%), and unvaccinated (73.6%). Results from logistic regression suggest that participants were more likely to be vaccinated if they received a recommendation from a healthcare provider (OR=5.15), received the influenza vaccine during the previous year (OR=3.56), or knew that Zostavax(®) was recommended for individuals over 60 years of age (OR=3.55). The most frequently provided reasons for being unvaccinated were "haven't gotten around to it/forgot" (27.2%) and "didn't know it was needed" (27.1%). After the educational session, the majority (72.5%) of unvaccinated patients were interested in speaking with their pharmacist or physician about receiving Zostavax(®). Analysis suggests that interest differed across initial reason for being unvaccinated (χ(2)=64.44; p<0.01). IMPLICATIONS/ CONCLUSIONS: Recommendations from healthcare providers are valued by patients and can improve vaccination rates. The patient education program increased interest in receiving Zostavax(®) and this interest differed depending on the reason provided for being unvaccinated.
Authors: La'Marcus T Wingate; Keisha Stubbs; Iman Ahmed; Rachel K Mayaka; Mary K Maneno; Earl Ettienne; Oluchi Elekwachi; Veronica Clarke-Tasker Journal: Int J Environ Res Public Health Date: 2018-09-27 Impact factor: 3.390
Authors: Brandon J Patterson; Philip O Buck; Desmond Curran; Desirée Van Oorschot; Justin Carrico; William L Herring; Yuanhui Zhang; Jeffrey J Stoddard Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-05-26